Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety profile of brentuximab vedotin sequentially and in combination with multi-agent chemotherapy in front-line treatment for CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma. It is a phase 1, open-label, dose escalation study in three arms designed to define the MTD, PK, immunogenicity, and anti-tumor activity of brentuximab vedotin in sequence and in combination with multi-agent front-line chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01309789
Study type Interventional
Source Seattle Genetics, Inc.
Contact
Status Completed
Phase Phase 1
Start date February 2011
Completion date February 28, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant N/A
Completed NCT02158975 - Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Phase 2
Completed NCT00043368 - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) Phase 2
Completed NCT00069238 - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Phase 2
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Active, not recruiting NCT03703375 - Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Phase 3
Recruiting NCT05476770 - Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Phase 1
Completed NCT00038376 - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Phase 2
Recruiting NCT03161223 - Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03902184 - IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Phase 2
Recruiting NCT05398614 - SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies Phase 1
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Completed NCT04121507 - ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Phase 2
Completed NCT04136275 - CAR-37 T Cells In Hematologic Malignancies Phase 1
Recruiting NCT03921879 - Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma Phase 1
Terminated NCT03154710 - Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response N/A
Recruiting NCT05466318 - ChiCGB vs BEAM in High-risk or R/R Lymphomas Phase 3
Recruiting NCT04928105 - Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma N/A
Withdrawn NCT04233697 - Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Phase 1
Recruiting NCT05557903 - Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL Phase 1